Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Eli Lilly and Company

7 shared events · Importance 3 · Last updated Jun 12, 2026

Importance
3
Shared Events
7
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
53
Domestic
United States — Food and Drug Administration: The United States — Food and Drug Administration approved Eli Lilly and Company's weight loss pill, Foundayo, impacting the pharmaceutical market.
Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
17
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration has cleared the CareMiBrain system for use and has approved new monoclonal antibody treatments for Alzheimer's Disease, creating a market for the PET scans.
Eli Lilly and Company: Eli Lilly and Company developed Kisunla, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
0
Business
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
0
Regulatory
Dec 22, 2025 · 23 articles
0
Regulatory
Feb 07, 2026 · 6 articles
0
Business
Apr 01, 2026 · 7 articles
0
International
Apr 01, 2026 · 16 articles
NEWSDESK
Explore this relationship live

Track how United States — Food and Drug Administration and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.